US Patent US10555556B2 declared invalid in infringement case

Sep.21.2022
US Patent US10555556B2 declared invalid in infringement case
Philip Morris lost patent infringement case in the US and its patent was invalidated, impacting e-cigarette product development.

Recently, in Case No.1:20-cv-0039-LO-TCB, Phimosis International accused R.J. Reynolds of patent infringement with No.US10555556B2, but the patent has since been invalidated in the U.S. after a lengthy legal battle that ended in Phimosis International's defeat. What does this ruling mean for the development of domestic electronic cigarette products?


Author bio: Lawyer Tang Shunliang is a specialized attorney in the field of new tobacco at the Beijing Zhong Lun Wen De Kunming law firm.


Part 1: Case Review


In case number 1:20-cv-0039-LO-TCB, R.J. Reynolds has brought a lawsuit against Phimow International for copyright infringement. Phimow International has responded by countersuing R.J. Reynolds for a series of patent infringement cases, highlighting the intense nature of the patent litigation between these two parties.


The case identifier is 1:20-cv-0039-LO-TCB.


On June 15, 2022, the Eastern District Court of Virginia ruled that R.J. Reynolds had infringed on two electronic cigarette technology patents owned by Philip Morris, identified as No. US9814265 and No. US10104911. As a result, they were ordered to pay $10.76 million in damages.


In this case, Phemo International has presented several weapons in its charge of infringement, including the patent No. US10555556B2, and has provided extensive evidence and reasoning to accuse VUSE VIBE of continuous infringement since June 29, 2022, specifically violating the first right claim of the patent. If this charge is proven, the compensation amount will not be limited to 10.76 million.


The R.J. Reynolds company has responded by stating that the patent should not have been granted. This is why there is now news of the recent invalidation of the patent.


Phimo International files a counter lawsuit against R.J. Reynolds for patent infringement of No.US10555556B2.


In its lawsuit, Philip Morris International compared its product VUSE VIBE to the patent No.US10555556B2 and argued that VUSE VIBE falls within the protection scope of "claim 1". However, the lawsuit fails to provide a comparison of whether VUSE VIBE contains the "first and second capillary" related technical features. Even if the patent is not found to be "invalid", it may still not constitute infringement (interested readers can download and read the legal documents).


Previously, Philip Morris International launched a patent lawsuit against British American Tobacco in Germany using patent "EP2282649," which is similar to a capillary oil guide. The court ruled in favor of British American Tobacco, stating that there was no infringement, resulting in Philip Morris International losing the case.


What is the technology solution protected by Claim 1 of patent No.US10555556B2?


A cylinder (commonly known as an e-cigarette) used in an aerosol generation system comprises a liquid storage portion that includes a pod container to maintain the liquid aerosol formation matrix. The pod container has an opening and at least two fluidly connected components (oil guiding components) form the liquid storage portion. All e-liquids need a corresponding storage component.


The first component of the liquid storage section includes:


The first capillary material, including various oil-conducting materials, fiber such as cotton, porous materials like ceramics, is used to evenly distribute the heat generating element for the e-cigarette. It is located near the opening of the shell. The second capillary material comes into contact with the first material and is separated from the opening by the first material (and does not come into contact with the heating sheet). Additionally, the second component of the liquid storage portion includes:


This refers to a device that utilizes an aerosol-forming matrix (e-liquid) to maintain a liquid state and supply the resulting aerosol-forming matrix to a container (e-liquid reservoir) made of a second capillary material. The device includes a fluid-permeable heating element (e-liquid permeator) that extends over the opening of the shell and the average pore size or porosity of the first capillary material is smaller than that of the second capillary material.


The key issue addressed by this patent is:


By setting up two guiding capillaries, the e-liquid is evenly distributed and atomized in the heater, ensuring no waste or reductions in e-liquid due to a decrease in volume or change in angle. This guarantees a high-quality vaping experience with every puff.


2.2 Common oil leakage issues have been resolved. However, the corresponding Mesh products still suffer from oil leakage problems.


The key technology of this plan is:


The use of two different types of oil-conducting materials achieves an even distribution of e-liquid to the heating element according to the frequency of vaping, resulting in improved vaporization efficiency. Claim 1 is not limited to a specific structural form and various forms and materials of oil-conducting materials and heaters are given as examples, making the scope of the invention broad. The technical solution provided in the manual is worth studying and learning from, and perhaps even finding better improvements. To aid readers in analysis, the figures have been marked by the author.


Figure 1 shows the overall technical plan, taking reference from Mesh and IQOS VEEV e-cigarettes. The core principle of oil storage, oil delivery and atomization is presented in Figure 2. Figure 3 illustrates the axial flow of oil passing through the heater and being uniformly released as smoke through the porous ceramic. Figure 4 demonstrates the radial oil delivery system (similar to traditional cotton core + metal wire) for atomization.


Closing Remarks


The ongoing patent wars between two tobacco giants indicate that both HNB and electronic vaporizer companies may continue to face legal challenges. It is possible that tobacco corporations have not yet turned their attention to Chinese electronic cigarette manufacturers, possibly due to other priorities.


However, their weapons arsenal is indeed very extensive, their research and development speed is very fast, and they are constantly laying out new patents.


Attachment 1: Global Distribution of Patents in the Same Cluster


Attachment 2: Patent Texts from Various Countries


Attachment 3: US Patent and Trademark Office invalidity decision.


Statement:


1. This article is intended for internal research and communication within the industry. It does not provide any investment or brand recommendations. This article should not be used as the basis for any investments. 2. The data and analysis conclusions mentioned in this article have not been confirmed in writing with the companies involved. Therefore, all information should be verified with official company releases.


This article is an original creation of 2FIRSTS Technology Co. Ltd. in Shenzhen. The copyright and usage rights belong to the company and no individual or organization is allowed to use, reproduce or copy the content for commercial purposes without authorization. Any infringement of the company's copyright will be subject to legal action.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14
China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang Industrial Co., Ltd. has filed a patent application for an oral nicotine delivery product designed to let users actively adjust nicotine release. The product embeds two types of nicotine reservoirs with different wall thicknesses and positions inside a deformable matrix. Pressure applied with the tongue or lips can rupture the reservoirs and accelerate nicotine release. In simulated oral tests, several patent examples showed sharply higher peak nicotine release rates as applied force increased from 0 N to 1 N and 3 N. The filing explores a shift from preset release profiles toward user-triggered nicotine delivery.
Sep.01
 PMI Opens Generative AI Center in Portugal to Support Global Operations
PMI Opens Generative AI Center in Portugal to Support Global Operations
According to information released by Portugal’s Trade & Investment Agency (AICEP) in July 2026, Philip Morris International (PMI) has established a global Generative Artificial Intelligence Factory (GenAI Factory) at its Portuguese subsidiary Tabaqueira. The center will support PMI’s global operations by developing and deploying AI solutions focused on industrial process optimization, data analytics, operational automation and AI application development. The initiative strengthens Portugal’s role in PMI’s global technology and innovation network.
Aug.27
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation Limited has been granted a Chinese invention patent covering 6-methylnicotine salt formulations and their use in oral and vaping products. The technology forms salts between 6-methylnicotine and alicyclic carboxylic acids, with granted claims extending to oral products, atomization substrates and electronic atomization devices. Applicant-generated tests reported differences in oxidation stability, in-vitro cytotoxicity and aerosol heavy-metal performance compared with selected benzoate or lactate controls. HG Innovation is directly linked to the broader IMiracle and ELFBAR business network.
Sep.04
PMI Global Communications Chief Moira Gilchrist: Why AI Matters More Than Ever in the Smoke-Free Transition
PMI Global Communications Chief Moira Gilchrist: Why AI Matters More Than Ever in the Smoke-Free Transition
Philip Morris International (PMI) Chief Global Communications Officer Moira Gilchrist said artificial intelligence is changing how companies understand audiences, manage owned information channels and communicate business transformation. PMI is using AI-generated audience personas to test messaging while optimizing its corporate website and other owned channels for large language models. As PMI continues its transition from cigarettes toward smoke-free products, Gilchrist said owned data and corporate channels are becoming increasingly important in demonstrating the scale of that transformation.
Aug.26
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands has agreed to acquire 100% of Swedish modern oral nicotine company Yoik Group AB for an initial SEK515 million, equivalent to about US$53.9 million, plus a deferred payment linked to performance over the next two years. Yoik owns nicotine pouch brand Helwit, which held about 3.4% of Sweden’s modern oral nicotine market over the past 12 months. Imperial says the acquisition will more than double its existing share of the Swedish market. Helwit is also sold elsewhere in the Nordics, through European online channels and in selected UK retail outlets.
Sep.08